Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 1/23/23 → 11/2/26 |
22-HEM-19-MSD: A Phase 3 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-Refractory, Relapsed or Refractory Classical Hodgkin Lymphoma
- Munker, Reinhold (PI)